The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
CALQUENCE AstraZeneca Pty Ltd
Product name
CALQUENCE
Sponsor
Accepted date
Jan-2025
Active ingredients
acalabrutinib maleate monohydrate
Proposed indication
CALQUENCE (acalabrutinib) is for the treatment of chronic lymphocytic leukaemia or small lymphocytic lymphoma (either as a monotherapy or in combination with other anticancer drugs).
Application type
C (new indication)
Publication date
Jan-2025